Table 4.

Oncological outcomes in randomized trials of neoadjuvant androgen deprivation therapy and radical prostatectomy versus immediate radical prostatectomy alone for clinically localized prostate cancer

Author	Year	Total patients	Clinical stage	Neoadjuvant therapy	Therapy duration	BCR/PSA progression (%)	Local recurrence (%)	Met disease (%)	Follow-up	Overall survival (%)
Witjes et al.[53]	1997	354	T2-3N0M0	Goserelin, Flutamide	3 months	Neo 22, RP 23			15 months
Aus et al.[54]	1998	122	T1b-3aNxM0	Triptorelin, Cyproterone	3 months	Neo 26, RP 22			38 months
Schulman et al.*[56]	2000	402	T2-3N0M0	Goserelin, Flutamide	3 months	Neo 26, RP 33	Neo 10, RP 16	Neo 7, RP 6	4 years	Neo 96, RP 96
Aus et al.*[62]	2002	126	T1b-3aNxM0	Triptorelin, Cyproterone	3 months	Neo 33, RP 29		Neo 5, RP 3	7 years	Neo 83, RP 86
Soloway et al.*[58]	2002	303	T2bNxM0	Leuprolide, Flutamide	3 months	Neo 35, RP 32			5 years
Klotz et al.*[63]	2003	213	T1b-T2c	Cyproterone	3 months	Neo 38, RP 34		Neo 5, RP 1	6 years	Neo 93, RP 95
Prezioso et al.[59]	2004	183	T1a-2bN0M0	Leuprolide, Cyproterone	3 months	Neo 10, RP 16
Yee et al.*[61]	2010	148	T1b-T3	Goserelin, Flutamide	3 months	Neo 24, RP 20	Neo 1, RP 2	Neo 4, RP 5	8 years	Neo 86, RP 92

*Follow-up report of prior study. BCR=Biochemical recurrence, Met=Metastasis; Neo=Neoadjuvant androgen deprivation therapy, OS=Overall survival, RP=Radical prostatectomy, PSA=Prostate specific antigen